Abstract
The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Current Neuropharmacology
Title:The Role of IRE1 Signaling in the Central Nervous System Diseases
Volume: 16 Issue: 9
Author(s): Haibo Ni, Qin Rui, Di Li*, Rong Gao and Gang Chen
Affiliation:
- Department of Translational Medicine Center, The First People`s Hospital of Zhangjiagang City, Suzhou, Jiangsu,China
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Abstract: The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Export Options
About this article
Cite this article as:
Ni Haibo , Rui Qin , Li Di *, Gao Rong and Chen Gang, The Role of IRE1 Signaling in the Central Nervous System Diseases, Current Neuropharmacology 2018; 16 (9) . https://dx.doi.org/10.2174/1570159X16666180416094646
DOI https://dx.doi.org/10.2174/1570159X16666180416094646 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia
Reviews on Recent Clinical Trials Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Beneficial Effects of Corn Silk on Metabolic Syndrome
Current Pharmaceutical Design Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Does the Association Between Anxiety and Parkinsons Disease Really Exist? A Literature Review
Current Psychiatry Reviews Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Statins as Antihypertensives
Recent Patents on Cardiovascular Drug Discovery Antioxidant Properties and Medicinal Uses of Some Crataegus Spp. (Hawthorn) Including <i>C. meyeri</i> and <i>C. pontica</i>
Current Nutrition & Food Science The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design Sepsis: The Involvement of Platelets and the Current Treatments
Current Molecular Pharmacology Fatal Lactic Acidosis Precipitated by Nifedipine in a Patient Treated with Disulfiram and Antiretrovirals
Drug Metabolism Letters Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe
Current Drug Metabolism